Progress of small molecular inhibitors in the development of anti-influenza virus agents

• Published in: Theranostics 2017-01, Vol.7 (4), p.826-845
• Main Authors: Wu, Xiaoai, Wu, Xiuli, Sun, Qizheng, Zhang, Chunhui, Yang, Shengyong, Li, Lin, Jia, Zhiyun
• Format: Article
• Language: English
• Subjects: Animals; Antiviral Agents - isolation & purification; Antiviral Agents - pharmacology; Drug Discovery - trends; Humans; Orthomyxoviridae - drug effects; Review
• ISSN: 1838-7640; 1838-7640
• DOI: 10.7150/thno.17071

The influenza pandemic is a major threat to human health, and highly aggressive strains such as H1N1, H5N1 and H7N9 have emphasized the need for therapeutic strategies to combat these pathogens. Influenza anti-viral agents, especially active small molecular inhibitors play important roles in controlling pandemics while vaccines are developed. Currently, only a few drugs, which function as influenza neuraminidase (NA) inhibitors and M2 ion channel protein inhibitors, are approved in clinical. However, the acquired resistance against current anti-influenza drugs and the emerging mutations of influenza virus itself remain the major challenging unmet medical needs for influenza treatment. It is highly desirable to identify novel anti-influenza agents. This paper reviews the progress of small molecular inhibitors act as antiviral agents, which include hemagglutinin (HA) inhibitors, RNA-dependent RNA polymerase (RdRp) inhibitors, NA inhibitors and M2 ion channel protein inhibitors etc. Moreover, we also summarize new, recently reported potential targets and discuss strategies for the development of new anti-influenza virus drugs.